Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System

• Autores principales: Giuseppe Cicala (Autor), Giulia Russo (Autor), Vincenza Santoro (Autor), Tindara Franchina (Autor), Nicola Silvestris (Autor), Mariacarmela Santarpia (Autor), Edoardo Spina (Autor), Maria Antonietta Barbieri (Autor)
• Formato: Libro
• Publicado: MDPI AG, 2024-09-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

<b>Background/Objectives</b>: Monoclonal antibodies (mAbs) have revolutionized multiple myeloma (MM) treatment. However, post-marketing data on their neuropsychiatric safety are limited. This study aimed to evaluate neuropsychiatric adverse events (AEs) related to mAbs used for MM throug...